Kodiak Sciences (KOD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 2, 2026, to be held virtually for shareholders of record as of April 6, 2026.
Shareholders are encouraged to review proxy materials online and can request paper or email copies if desired.
Voting matters and shareholder proposals
Election of three Class II directors: Charles A. Bancroft, Bassil I. Dahiyat, Ph.D., and Taiyin Yang, Ph.D.
Advisory vote to approve named executive officer compensation.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026.
Proxies may vote on other business that arises during the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all three proposals presented at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kodiak Sciences
- Shareholders will vote on directors, executive pay, and auditor, with a focus on performance and ESG.KOD
Proxy filing23 Apr 2026 - Strong clinical milestones and solid cash position support continued late-stage development.KOD
Q4 202531 Mar 2026 - Late-stage retina therapies show strong efficacy and durability, targeting major unmet needs.KOD
Corporate presentation16 Mar 2026 - Lead retinal programs advance to pivotal trials with improved efficacy and strong financial backing.KOD
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Advancing three late-stage retinal programs with durable, multi-mechanism therapies and strong funding.KOD
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Late-stage pipeline advances with enhanced ABCD platform, strong cash, and key data in 2025–26.KOD
R&D Day 202420 Jan 2026 - Enhanced formulations and pivotal studies set the stage for major 2025–2026 clinical milestones.KOD
Jefferies London Healthcare Conference 202413 Jan 2026 - Late-stage retina assets advance toward pivotal data and launches, with strong financial runway.KOD
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Pivotal phase III trials for enhanced Tarcocimab and KSI-501 approach major data readouts.KOD
7th Annual Evercore ISI HealthCONx Conference12 Jan 2026